Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Tumor-Agnostic 6Thoracic 5Other solid neoplasm 3Gynecologic 2Genitourinary 2CNS 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × cediranib × Head & Neck × Clear all
NCT00243347 2013-10-17

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

AstraZeneca

Phase 1 Completed
19 enrolled 7 charts
Head & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡